{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:12:00Z","timestamp":1788862320521,"version":"build-2803163510"},"reference-count":66,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background\/Objectives: This study evaluated the metabolic effects of empagliflozin, an SGLT2 inhibitor (SGLT2i), in type 2 diabetes patients. Methods: In an observational cohort study, 42 patients received empagliflozin for 1 month, with serum and urine analyzed for IL-6, NT-proBNP, iron metabolism markers, and electrolytes. Another group was treated for 3 months, assessing lipoprotein and glycoprotein profiles, IL-6, and NT-proBNP. Results: Empagliflozin increased serum magnesium (mean difference = 0.26 \u00b1 0.38 mg\/dL, p &lt; 0.0001), hemoglobin (mean difference = 0.45 \u00b1 0.78 g\/dL, p = 0.0005), and hematocrit (mean difference = 1.74 \u00b1 2.08%, p &lt; 0.0001), while decreasing ferritin (mean difference = \u221229.23 \u00b1 51.97 ng\/mL) and transferrin saturation (mean difference = \u22123.65 \u00b1 7.22%). NT-proBNP and IL-6 levels trended lower (non-significant). Lipoprotein profiling showed a neutral effect. Conclusions: Empagliflozin positively affected serum magnesium, iron metabolism, and inflammatory markers without altering lipoprotein profiles. Further research is needed to elucidate SGLT2i\u2019s molecular mechanisms underlying their pleiotropic\u2013cardioprotective effects.<\/jats:p>","DOI":"10.3390\/biomedicines14092016","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:02:24Z","timestamp":1788858144000},"page":"2016","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic and Lipoprotein Changes in Type 2 Diabetes Patients Treated with Empagliflozin"],"prefix":"10.3390","volume":"14","author":[{"given":"Evagelia E.","family":"Habeos","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1519-3776","authenticated-orcid":false,"given":"Georgios K.","family":"Markantes","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Parthymou","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Dimitropoulos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1232-3192","authenticated-orcid":false,"given":"George I.","family":"Habeos","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-989X","authenticated-orcid":false,"given":"Marios","family":"Papasotiriou","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Kidney Transplantation, University Hospital of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Marangos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-6067","authenticated-orcid":false,"given":"Dionysios V.","family":"Chartoumpekis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, School of Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.2014.732","article-title":"Prevalence of childhood and adult obesity in the United States, 2011\u20132012","volume":"311","author":"Ogden","year":"2014","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: A meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ndt\/17.suppl_1.67","article-title":"How should we manage anaemia in patients with diabetes?","volume":"17","author":"Dikow","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1159\/000081058","article-title":"Anemia and diabetes","volume":"24","author":"Deray","year":"2004","journal-title":"Am. J. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/diacare.26.4.1164","article-title":"Unrecognized anemia in patients with diabetes: A cross-sectional survey","volume":"26","author":"Thomas","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1479164118782872","article-title":"Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial","volume":"15","author":"Takashima","year":"2018","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"Muskiet","year":"2020","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/dom.13631","article-title":"Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial","volume":"21","author":"Gallo","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults with Type 2 Diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights from a Mediation Analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: A post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/ndt\/gfae198","article-title":"Canagliflozin and iron metabolism in the CREDENCE trial","volume":"40","author":"Koshino","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: A prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jdi.12774","article-title":"Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension","volume":"9","author":"Kimura","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes: A Meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdi.12760","article-title":"No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis","volume":"9","author":"Cai","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"117236","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jjcc.2020.06.006","article-title":"Administration of eicosapentaenoic acid may alter lipoprotein particle heterogeneity in statin-treated patients with stable coronary artery disease: A pilot 6-month randomized study","volume":"76","author":"Tani","year":"2020","journal-title":"J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1194\/jlr.D050120","article-title":"Liposcale: A novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy","volume":"56","author":"Mallol","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Malo, A.I., Rull, A., Girona, J., Domingo, P., Fuertes-Martin, R., Amigo, N., Rodriguez-Borjabad, C., Martinez-Micaelo, N., Leal, M., and Peraire, J. (2020). Glycoprotein Profile Assessed by (1)H-NMR as a Global Inflammation Marker in Patients with HIV Infection. A Prospective Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051344"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1021\/acs.jproteome.8b00411","article-title":"Characterization of (1)H NMR Plasma Glycoproteins as a New Strategy To Identify Inflammatory Patterns in Rheumatoid Arthritis","volume":"17","author":"Taverner","year":"2018","journal-title":"J. Proteome Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2337\/dc22-0331","article-title":"Measurement of Serum N-Glycans in the Assessment of Early Vascular Aging (Arterial Stiffness) in Adults With Type 1 Diabetes","volume":"45","author":"Llaurado","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101549","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors\u2014Do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rosenblum, S.L. (2023). Inflammation, dysregulated iron metabolism, and cardiovascular disease. Front. Aging, 4.","DOI":"10.3389\/fragi.2023.1124178"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bbagen.2008.08.006","article-title":"Iron metabolism in the anemia of chronic disease","volume":"1790","author":"Weiss","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00392-010-0140-z","article-title":"Inflammation increases NT-proBNP and the NT-proBNP\/BNP ratio","volume":"99","author":"Jensen","year":"2010","journal-title":"Clin. Res. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s10753-014-0107-8","article-title":"GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes","volume":"38","author":"Dungan","year":"2015","journal-title":"Inflammation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12950-023-00358-7","article-title":"Towards clinical application of GlycA and GlycB for early detection of inflammation associated with (pre)diabetes and cardiovascular disease: Recent evidence and updates","volume":"20","author":"Fung","year":"2023","journal-title":"J. Inflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.coph.2021.08.013","article-title":"Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus","volume":"61","author":"Kane","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","article-title":"Lipoproteins in chronic kidney disease: From bench to bedside","volume":"42","author":"Speer","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Xu, J., Hirai, T., Koya, D., and Kitada, M. (2021). Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010137"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: A meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.coph.2020.06.001","article-title":"Evolving understanding of cardiovascular protection by SGLT2 inhibitors: Focus on renal protection, myocardial effects, uric acid, and magnesium balance","volume":"54","author":"Ray","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jcmm.17115","article-title":"Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis","volume":"26","author":"Tian","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the Effects of Canagliflozin on Heart Failure in Patients with Type 2 Diabetes","volume":"8","author":"Li","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"102702","DOI":"10.1016\/j.dsx.2022.102702","article-title":"Increase in hematocrit with SGLT-2 inhibitors\u2014Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?","volume":"17","author":"Ekanayake","year":"2023","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/dom.14517","article-title":"Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study","volume":"23","author":"Thiele","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e14890","DOI":"10.14814\/phy2.14890","article-title":"Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus","volume":"9","author":"Hare","year":"2021","journal-title":"Physiol. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2011-09-380337","article-title":"Deletion of HIF-2alpha in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice","volume":"119","author":"Mastrogiannaki","year":"2012","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jchf.2023.07.010","article-title":"Short-Term Changes in Peak VO(2) After Initiation of Dapagliflozin in Heart Failure Across Iron Status","volume":"11","author":"Lorenzo","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.2337\/dc20-0456","article-title":"Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights from Large-Scale Proteomics","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.exphem.2007.01.026","article-title":"Erythropoietin and iron-restricted erythropoiesis","volume":"35","author":"Goodnough","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e006541","DOI":"10.1161\/CIRCHEARTFAILURE.119.006541","article-title":"Comparison of BNP and NT-proBNP in Patients with Heart Failure and Reduced Ejection Fraction","volume":"13","author":"Rorth","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jacc.2021.07.046","article-title":"Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial","volume":"78","author":"Januzzi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/annrheumdis-2012-202848","article-title":"N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: Results from the Norfolk Arthritis Registry (NOAR)","volume":"73","author":"Mirjafari","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gohari, S., Ismail-Beigi, F., Mahjani, M., Ghobadi, S., Jafari, A., Ahangar, H., and Gohari, S. (2023). The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: A systematic review and meta-analysis of randomized controlled trials. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01512-1"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12933-023-01904-6","article-title":"Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction\u2014A post-hoc analysis of the EMMY trial","volume":"22","author":"Benedikt","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106667","DOI":"10.1016\/j.phrs.2023.106667","article-title":"Neutral effect of SGLT2 inhibitors on lipoprotein metabolism: From clinical evidence to molecular mechanisms","volume":"188","author":"Osto","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2021.06.915","article-title":"Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: Data from a randomized, placebo-controlled study","volume":"330","author":"Rau","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12933-017-0608-5","article-title":"Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/dom.13990","article-title":"The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol","volume":"22","author":"Bouter","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-017-1321-6","article-title":"GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk","volume":"15","author":"Connelly","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: A randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/9\/2016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:25:27Z","timestamp":1788859527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/9\/2016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["biomedicines14092016"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines14092016","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}